The State of the Art: Atrial Fibrillation Epidemiology, Prevention, and Treatment

Mayo Clinic Proceedings

Volumn 91, Issue 12, 2016, Pages 1778-1810

  Morin, Daniel P ^a,b   Bernard, Michael L ^a   Madias, Christopher ^c   Rogers, Paul A ^a   Thihalolipavan, Sudarone ^a   Estes, N A Mark ^d  

^a OCHSNER MEDICAL CENTER   (United States)

^b UNIVERSITY OF QUEENSLAND   (Australia)

^c RUSH UNIVERSITY MEDICAL CENTER   (United States)

^d TUFTS MEDICAL CENTER   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

ACETYLSALICYLIC ACID; AMIODARONE; ANTIARRHYTHMIC AGENT; ANTITHROMBOCYTIC AGENT; APIXABAN; CLOPIDOGREL; DABIGATRAN; DOFETILIDE; EDOXABAN; FLECAINIDE; PROPAFENONE; SOTALOL; WARFARIN; ANTICOAGULANT AGENT;

ABLATION CATHETER; AGE; ALCOHOL CONSUMPTION; ANTICOAGULANT THERAPY; ANTIHYPERTENSIVE THERAPY; ATRIAL FIBRILLATION; BLEEDING; BODY MASS; CEREBROVASCULAR ACCIDENT; CHADS2 SCORE; CLINICAL TRIAL (TOPIC); COMORBIDITY; CONGESTIVE HEART FAILURE; DIABETES MELLITUS; DIASTOLIC BLOOD PRESSURE; DRUG CONTRAINDICATION; DRUG EFFICACY; DRUG INDICATION; EQUIPMENT DESIGN; GENDER; HEALTH CARE COST; HEART LEFT VENTRICLE HYPERTROPHY; HEART RATE; HEART RHYTHM; HIGH RISK PATIENT; HUMAN; HYPERTENSION; INTERVENTIONAL CARDIOVASCULAR PROCEDURE; LEFT ATRIAL APPENDAGE CLOSURE DEVICE; NEW YORK HEART ASSOCIATION CLASS; OBESITY; PATHOPHYSIOLOGY; PATIENT CARE; PATIENT SELECTION; PHASE 2 CLINICAL TRIAL (TOPIC); POSITIVE END EXPIRATORY PRESSURE; PUBLIC HEALTH PROBLEM; RACE; RANDOMIZED CONTROLLED TRIAL (TOPIC); REVIEW; RISK FACTOR; RISK REDUCTION; SLEEP DISORDERED BREATHING; SURGICAL APPROACH; SYSTOLIC BLOOD PRESSURE; TREATMENT PLANNING; TREATMENT RESPONSE; TREND STUDY; ADULT; AGED; ELECTROCARDIOGRAPHY; MIDDLE AGED; TRANSESOPHAGEAL ECHOCARDIOGRAPHY;

ADULT; AGED; ANTICOAGULANTS; ATRIAL FIBRILLATION; CLINICAL TRIALS AS TOPIC; ECHOCARDIOGRAPHY, TRANSESOPHAGEAL; ELECTROCARDIOGRAPHY; HUMANS; MIDDLE AGED;

EID: 85002899145     PISSN: 00256196     EISSN: 19425546     Source Type: Journal    
DOI: 10.1016/j.mayocp.2016.08.022     Document Type: Review

References (255)

1. 1 Lewis, T., Report CXIX. Auricular fibrillation: a common clinical condition. Br Med J, 2(2552), 1909, 1528.
2. 2 Rothberger, C., Winterberg, H., Vorhofflimmern und arrhythmia perpetua. Wien Klin Wochenschr 22 (1909), 839–844.
3. 3 Mackenzie, J., Observations on the process which relsults in auricular fibrillation. Br Med J 2:3211 (1922), 71–73.
4. 4 Marijon, E., Le Heuzey, J.Y., Connolly, S., et al., RE-LY Investigators. Causes of death and influencing factors in patients with atrial fibrillation: a competing-risk analysis from the randomized evaluation of long-term anticoagulant therapy study. Circulation 128:20 (2013), 2192–2201.
5. 5 Thrall, G., Lane, D., Carroll, D., Lip, G.Y., Quality of life in patients with atrial fibrillation: a systematic review. Am J Med 119:5 (2006), 448e1–448e19.
6. 6 Chugh, S.S., Havmoeller, R., Narayanan, K., et al. Worldwide epidemiology of atrial fibrillation: a Global Burden of Disease 2010 Study. Circulation 129:8 (2014), 837–847.
7. 7 Ball, J., Carrington, M.J., McMurray, J.J., Stewart, S., Atrial fibrillation: profile and burden of an evolving epidemic in the 21st century. Int J Cardiol 167:5 (2013), 1807–1824.
8. 8 Amponsah, M.K., Benjamin, E.J., Magnani, J.W., Atrial fibrillation and race—a contemporary review. Curr Cardiovasc Risk Rep 7:5 (2013), 1–16.
9. 9 Colilla, S., Crow, A., Petkun, W., Singer, D.E., Simon, T., Liu, X., Estimates of current and future incidence and prevalence of atrial fibrillation in the U.S. adult population. Am J Cardiol 112:8 (2013), 1142–1147.
10. 10 Benjamin, E.J., Levy, D., Vaziri, S.M., D'Agostino, R.B., Belanger, A.J., Wolf, P.A., Independent risk factors for atrial fibrillation in a population-based cohort: the Framingham Heart Study. JAMA 271:11 (1994), 840–844.
11. 11 Kannel, W.B., Benjamin, E.J., Status of the epidemiology of atrial fibrillation. Med Clin North Am 92:1 (2008), 17–40 ix.
12. 12 Lloyd-Jones, D.M., Wang, T.J., Leip, E.P., et al. Lifetime risk for development of atrial fibrillation: the Framingham Heart Study. Circulation 110:9 (2004), 1042–1046.
13. 13 Heeringa, J., van der Kuip, D.A., Hofman, A., et al. Prevalence, incidence and lifetime risk of atrial fibrillation: the Rotterdam study. Eur Heart J 27:8 (2006), 949–953.
14. 14 Piccini, J.P., Hammill, B.G., Sinner, M.F., et al. Incidence and prevalence of atrial fibrillation and associated mortality among Medicare beneficiaries, 1993-2007. Circ Cardiovasc Qual Outcomes 5:1 (2012), 85–93.
15. 15 Dewland, T.A., Olgin, J.E., Vittinghoff, E., Marcus, G.M., Incident atrial fibrillation among Asians, Hispanics, blacks, and whites. Circulation 128:23 (2013), 2470–2477.
16. 16 Alonso, A., Agarwal, S.K., Soliman, E.Z., et al. Incidence of atrial fibrillation in whites and African-Americans: the Atherosclerosis Risk in Communities (ARIC) study. Am Heart J 158:1 (2009), 111–117.
17. 17 Psaty, B.M., Manolio, T.A., Kuller, L.H., et al. Incidence of and risk factors for atrial fibrillation in older adults. Circulation 96:7 (1997), 2455–2461.
18. 18 Hernandez, M.B., Asher, C.R., Hernandez, A.V., Novaro, G.M., African American race and prevalence of atrial fibrillation: a meta-analysis. Cardiol Res Pract, 2012, 2012, 275624.
19. 19 Marcus, G.M., Alonso, A., Peralta, C.A., et al., Candidate-Gene Association Resource (CARe) Study. European ancestry as a risk factor for atrial fibrillation in African Americans. Circulation 122:20 (2010), 2009–2015.
20. 20 Humphries, K.H., Kerr, C.R., Connolly, S.J., et al. New-onset atrial fibrillation: sex differences in presentation, treatment, and outcome. Circulation 103:19 (2001), 2365–2370.
21. 21 Wang, T.J., Massaro, J.M., Levy, D., et al. A risk score for predicting stroke or death in individuals with new-onset atrial fibrillation in the community: the Framingham Heart Study. JAMA 290:8 (2003), 1049–1056.
22. 22 Friberg, J., Scharling, H., Gadsbøll, N., Truelsen, T., Jensen, G.B., Copenhagen City Heart Study. Comparison of the impact of atrial fibrillation on the risk of stroke and cardiovascular death in women versus men (The Copenhagen City Heart Study). Am J Cardiol 94:7 (2004), 889–894.
23. 23 Menezes, A.R., Lavie, C.J., De Schutter, A., et al. Lifestyle modification in the prevention and treatment of atrial fibrillation. Prog Cardiovasc Dis 58:2 (2015), 117–125.
24. 24 Braunwald, E., Shattuck lecture—cardiovascular medicine at the turn of the millennium: triumphs, concerns, and opportunities. N Engl J Med 337:19 (1997), 1360–1369.
25. 25 Thihalolipavan, S., Morin, D.P., Atrial fibrillation and heart failure: update 2015. Prog Cardiovasc Dis 58:2 (2015), 126–135.
26. 26 Stewart, S., Hart, C.L., Hole, D.J., McMurray, J.J., A population-based study of the long-term risks associated with atrial fibrillation: 20-year follow-up of the Renfrew/Paisley study. Am J Med 113:5 (2002), 359–364.
27. 27 Chiang, C.E., Naditch-Brûlé, L., Murin, J., et al. Distribution and risk profile of paroxysmal, persistent, and permanent atrial fibrillation in routine clinical practice: insight from the real-life global survey evaluating patients with atrial fibrillation international registry. Circ Arrhythm Electrophysiol 5:4 (2012), 632–639.
28. 28 Maisel, W.H., Stevenson, L.W., Atrial fibrillation in heart failure: epidemiology, pathophysiology, and rationale for therapy. Am J Cardiol 91:6A (2003), 2D–8D.
29. 29 Wang, T.J., Larson, M.G., Levy, D., et al. Temporal relations of atrial fibrillation and congestive heart failure and their joint influence on mortality: the Framingham Heart Study. Circulation 107:23 (2003), 2920–2925.
30. 30 Mamas, M.A., Caldwell, J.C., Chacko, S., Garratt, C.J., Fath-Ordoubadi, F., Neyses, L., A meta-analysis of the prognostic significance of atrial fibrillation in chronic heart failure. Eur J Heart Fail 11:7 (2009), 676–683.
31. 31 Nattel, S., Ionic determinants of atrial fibrillation and Ca2+ channel abnormalities: cause, consequence, or innocent bystander?. Circ Res 85:5 (1999), 473–476.
32. 32 Wijffels, M.C., Kirchhof, C.J., Dorland, R., Allessie, M.A., Atrial fibrillation begets atrial fibrillation: a study in awake chronically instrumented goats. Circulation 92:7 (1995), 1954–1968.
33. 33 Van den Berg, M.P., Tuinenburg, A.E., Crijns, H.J., Van Gelder, I.C., Gosselink, A.T., Lie, K.I., Heart failure and atrial fibrillation: current concepts and controversies. Heart 77:4 (1997), 309–313.
34. 34 Tomaselli, G.F., Marbán, E., Electrophysiological remodeling in hypertrophy and heart failure. Cardiovasc Res 42:2 (1999), 270–283.
35. 35 Li, D., Fareh, S., Leung, T.K., Nattel, S., Promotion of atrial fibrillation by heart failure in dogs: atrial remodeling of a different sort. Circulation 100:1 (1999), 87–95.
36. 36 Chen, Y.J., Chen, Y.C., Tai, C.T., Yeh, H.I., Lin, C.I., Chen, S.A., Angiotensin II and angiotensin II receptor blocker modulate the arrhythmogenic activity of pulmonary veins. Br J Pharmacol 147:1 (2006), 12–22.
37. 37 Dixen, U., Ravn, L., Soeby-Rasmussen, C., et al. Raised plasma aldosterone and natriuretic peptides in atrial fibrillation. Cardiology 108:1 (2007), 35–39.
38. 38 Conen, D., Tedrow, U.B., Koplan, B.A., Glynn, R.J., Buring, J.E., Albert, C.M., Influence of systolic and diastolic blood pressure on the risk of incident atrial fibrillation in women. Circulation 119:16 (2009), 2146–2152.
39. 39 Grundvold, I., Skretteberg, P.T., Liestøl, K., et al. Upper normal blood pressures predict incident atrial fibrillation in healthy middle-aged men: a 35-year follow-up study. Hypertension 59:2 (2012), 198–204.
40. 40 Lau, Y.F., Yiu, K.H., Siu, C.W., Tse, H.F., Hypertension and atrial fibrillation: epidemiology, pathophysiology and therapeutic implications. J Hum Hypertens 26:10 (2012), 563–569.
41. 41 Chen, L.Y., Bigger, J.T., Hickey, K.T., et al. Effect of intensive blood pressure lowering on incident atrial fibrillation and P-wave indices in the ACCORD blood pressure trial. [published online ahead of print] Am J Hypertens, October 16, 2015 doi: 10.1093/ajh/hpv172.
42. 42 Wachtell, K., Lehto, M., Gerdts, E., et al. Angiotensin II receptor blockade reduces new-onset atrial fibrillation and subsequent stroke compared to atenolol: the Losartan Intervention For End Point Reduction in Hypertension (LIFE) study. J Am Coll Cardiol 45:5 (2005), 712–719.
43. 43 Schmieder, R.E., Kjeldsen, S.E., Julius, S., McInnes, G.T., Zanchetti, A., Hua, T.A., VALUE Trial Group. Reduced incidence of new-onset atrial fibrillation with angiotensin II receptor blockade: the VALUE trial. J Hypertens 26:3 (2008), 403–411.
44. 44 Healey, J.S., Baranchuk, A., Crystal, E., et al. Prevention of atrial fibrillation with angiotensin-converting enzyme inhibitors and angiotensin receptor blockers: a meta-analysis. J Am Coll Cardiol 45:11 (2005), 1832–1839.
45. 45 Marott, S.C., Nielsen, S.F., Benn, M., Nordestgaard, B.G., Antihypertensive treatment and risk of atrial fibrillation: a nationwide study. Eur Heart J 35:18 (2014), 1205–1214.
46. 46 Pan, G., Zhou, X., Zhao, J., Effect of telmisartan on atrial fibrillation recurrences in patients with hypertension: a systematic review and meta-analysis. Cardiovasc Ther 32:4 (2014), 184–188.
47. 47 Pallisgaard, J.L., Lindhardt, T.B., Olesen, J.B., Hansen, M.L., Carlson, N., Gislason, G.H., Management and prognosis of atrial fibrillation in the diabetic patient. Expert Rev Cardiovasc Ther 13:6 (2015), 643–651.
48. 48 De Sensi, F., De Potter, T., Cresti, A., Severi, S., Breithardt, G., Atrial fibrillation in patients with diabetes: molecular mechanisms and therapeutic perspectives. Cardiovasc Diagn Ther 5:5 (2015), 364–373.
49. 49 Aksnes, T.A., Schmieder, R.E., Kjeldsen, S.E., Ghani, S., Hua, T.A., Julius, S., Impact of new-onset diabetes mellitus on development of atrial fibrillation and heart failure in high-risk hypertension (from the VALUE Trial). Am J Cardiol 101:5 (2008), 634–638.
50. 50 Huxley, R.R., Filion, K.B., Konety, S., Alonso, A., Meta-analysis of cohort and case-control studies of type 2 diabetes mellitus and risk of atrial fibrillation. Am J Cardiol 108:1 (2011), 56–62.
51. 51 Cariou, B., Charbonnel, B., Staels, B., Thiazolidinediones and PPARγ agonists: time for a reassessment. Trends Endocrinol Metab 23:5 (2012), 205–215.
52. 52 Chao, T.F., Leu, H.B., Huang, C.C., et al. Thiazolidinediones can prevent new onset atrial fibrillation in patients with non-insulin dependent diabetes. Int J Cardiol 156:2 (2012), 199–202.
53. 53 Gu, J., Liu, X., Wang, X., et al. Beneficial effect of pioglitazone on the outcome of catheter ablation in patients with paroxysmal atrial fibrillation and type 2 diabetes mellitus. Europace 13:9 (2011), 1256–1261.
54. 54 Wilson, L.D., Tsai, C.T., Heart failure-related atrial fibrillation: a new model for a new prevention strategy?. Heart Rhythm 5:3 (2008), 460–461.
55. 55 Yatsuya, H., Li, Y., Hilawe, E.H., et al. Global trend in overweight and obesity and its association with cardiovascular disease incidence. Circ J 78:12 (2014), 2807–2818.
56. 56 Vaziri, S.M., Larson, M.G., Lauer, M.S., Benjamin, E.J., Levy, D., Influence of blood pressure on left atrial size: the Framingham Heart Study. Hypertension 25:6 (1995), 1155–1160.
57. 57 Zhou, Y.T., Grayburn, P., Karim, A., et al. Lipotoxic heart disease in obese rats: implications for human obesity. Proc Natl Acad Sci U S A 97:4 (2000), 1784–1789.
58. 58 Pelat, M., Verwaerde, P., Merial, C., et al. Impaired atrial M(2)-cholinoceptor function in obesity-related hypertension. Hypertension 34:5 (1999), 1066–1072.
59. 59 Wang, T.J., Parise, H., Levy, D., et al. Obesity and the risk of new-onset atrial fibrillation. JAMA 292:20 (2004), 2471–2477.
60. 60 Tedrow, U.B., Conen, D., Ridker, P.M., et al. The long- and short-term impact of elevated body mass index on the risk of new atrial fibrillation the WHS (Women's Health Study). J Am Coll Cardiol 55:21 (2010), 2319–2327.
61. 61 Huxley, R.R., Lopez, F.L., Folsom, A.R., et al. Absolute and attributable risks of atrial fibrillation in relation to optimal and borderline risk factors: the Atherosclerosis Risk in Communities (ARIC) study. Circulation 123:14 (2011), 1501–1508.
62. 62 Knuiman, M., Briffa, T., Divitini, M., et al. A cohort study examination of established and emerging risk factors for atrial fibrillation: the Busselton Health Study. Eur J Epidemiol 29:3 (2014), 181–190.
63. 63 Frost, L., Hune, L.J., Vestergaard, P., Overweight and obesity as risk factors for atrial fibrillation or flutter: the Danish Diet, Cancer, and Health Study. Am J Med 118:5 (2005), 489–495.
64. 64 Pathak, R.K., Middeldorp, M.E., Meredith, M., et al. Long-Term Effect of Goal-Directed Weight Management in an Atrial Fibrillation Cohort: a long-term follow-up study (LEGACY). J Am Coll Cardiol 65:20 (2015), 2159–2169.
65. 65 Pathak, R.K., Elliott, A., Middeldorp, M.E., et al. Impact of CARDIOrespiratory FITness on arrhythmia recurrence in obese individuals with atrial fibrillation: the CARDIO-FIT study. J Am Coll Cardiol 66:9 (2015), 985–996.
66. 66 Hatem, S.N., Sanders, P., Epicardial adipose tissue and atrial fibrillation. Cardiovasc Res 102:2 (2014), 205–213.
67. 67 Mahajan, R., Lau, D.H., Brooks, A.G., et al. Electrophysiological, electroanatomical, and structural remodeling of the atria as consequences of sustained obesity. J Am Coll Cardiol 66:1 (2015), 1–11.
68. 68 Thanassoulis, G., Massaro, J.M., O'Donnell, C.J., et al. Pericardial fat is associated with prevalent atrial fibrillation: the Framingham Heart Study. Circ Arrhythm Electrophysiol 3:4 (2010), 345–350.
69. 69 Al Chekakie, M.O., Welles, C.C., Metoyer, R., et al. Pericardial Fat Is Independently Associated With Human Atrial Fibrillation. J Am Coll Cardiol 56:10 (2010), 784–788.
70. 70 Wong, C.X., Ganesan, A.N., Selvanayagam, J.B., Epicardial fat and atrial fibrillation: current evidence, potential mechanisms, clinical implications, and future directions. [published online ahead of print] Eur Heart J, March 1, 2016 doi: 10.1093/eurheartj/ehw045.
71. 71 Menz, V., Grimm, W., Hoffmann, J., Maisch, B., Alcohol and rhythm disturbance: the holiday heart syndrome. Herz 21:4 (1996), 227–231.
72. 72 Lowenstein, S.R., Gabow, P.A., Cramer, J., Oliva, P.B., Ratner, K., The role of alcohol in new-onset atrial fibrillation. Arch Intern Med 143:10 (1983), 1882–1885.
73. 73 Sengul, C., Cevik, C., Ozveren, O., et al. Acute alcohol consumption is associated with increased interatrial electromechanical delay in healthy men. Cardiol J 18:6 (2011), 682–686.
74. 74 Mandyam, M.C., Vedantham, V., Scheinman, M.M., et al. Alcohol and vagal tone as triggers for paroxysmal atrial fibrillation. Am J Cardiol 110:3 (2012), 364–368.
75. 75 Djoussé, L., Levy, D., Benjamin, E.J., et al. Long-term alcohol consumption and the risk of atrial fibrillation in the Framingham Study. Am J Cardiol 93:6 (2004), 710–713.
76. 76 Larsson, S.C., Drca, N., Wolk, A., Alcohol consumption and risk of atrial fibrillation: a prospective study and dose-response meta-analysis. J Am Coll Cardiol 64:3 (2014), 281–289.
77. 77 O'Keefe, J.H., Bhatti, S.K., Bajwa, A., DiNicolantonio, J.J., Lavie, C.J., Alcohol and cardiovascular health: the dose makes the poison…or the remedy. Mayo Clin Proc 89:3 (2014), 382–393.
78. 78 Young, T., Palta, M., Dempsey, J., Skatrud, J., Weber, S., Badr, S., The occurrence of sleep-disordered breathing among middle-aged adults. N Engl J Med 328:17 (1993), 1230–1235.
79. 79 Bradley, T.D., Floras, J.S., Sleep apnea and heart failure, part II: central sleep apnea. Circulation 107:13 (2003), 1822–1826.
80. 80 Bradley, T.D., Floras, J.S., Sleep apnea and heart failure, part I: obstructive sleep apnea. Circulation 107:12 (2003), 1671–1678.
81. 81 Gami, A.S., Pressman, G., Caples, S.M., et al. Association of atrial fibrillation and obstructive sleep apnea. Circulation 110:4 (2004), 364–367.
82. 82 Braga, B., Poyares, D., Cintra, F., et al. Sleep-disordered breathing and chronic atrial fibrillation. Sleep Med 10:2 (2009), 212–216.
83. 83 Kanagala, R., Murali, N.S., Friedman, P.A., et al. Obstructive sleep apnea and the recurrence of atrial fibrillation. Circulation 107:20 (2003), 2589–2594.
84. 84 Monahan, K., Brewster, J., Wang, L., et al. Relation of the severity of obstructive sleep apnea in response to anti-arrhythmic drugs in patients with atrial fibrillation or atrial flutter. Am J Cardiol 110:3 (2012), 369–372.
85. 85 Sauer, W.H., McKernan, M.L., Lin, D., Gerstenfeld, E.P., Callans, D.J., Marchlinski, F.E., Clinical predictors and outcomes associated with acute return of pulmonary vein conduction during pulmonary vein isolation for treatment of atrial fibrillation. Heart Rhythm 3:9 (2006), 1024–1028.
86. 86 Naruse, Y., Tada, H., Satoh, M., et al. Concomitant obstructive sleep apnea increases the recurrence of atrial fibrillation following radiofrequency catheter ablation of atrial fibrillation: clinical impact of continuous positive airway pressure therapy. Heart Rhythm 10:3 (2013), 331–337.
87. 87 Fein, A.S., Shvilkin, A., Shah, D., et al. Treatment of obstructive sleep apnea reduces the risk of atrial fibrillation recurrence after catheter ablation. J Am Coll Cardiol 62:4 (2013), 300–305.
88. 88 Patel, D., Mohanty, P., Di Biase, L., et al. Safety and efficacy of pulmonary vein antral isolation in patients with obstructive sleep apnea: the impact of continuous positive airway pressure. Circ Arrhythm Electrophysiol 3:5 (2010), 445–451.
89. 89 Neilan, T.G., Farhad, H., Dodson, J.A., et al. Effect of sleep apnea and continuous positive airway pressure on cardiac structure and recurrence of atrial fibrillation. J Am Heart Assoc, 2(6), 2013, e000421.
90. 90 Abed, H.S., Wittert, G.A., Leong, D.P., et al. Effect of weight reduction and cardiometabolic risk factor management on symptom burden and severity in patients with atrial fibrillation: a randomized clinical trial. JAMA 310:19 (2013), 2050–2060.
91. 91 Pathak, R.K., Middeldorp, M.E., Lau, D.H., et al. Aggressive Risk Factor Reduction Study for Atrial Fibrillation and implications for the outcome of ablation: the ARREST-AF cohort study. J Am Coll Cardiol 64:21 (2014), 2222–2231.
92. 92 Stewart, S., Murphy, N.F., Walker, A., McGuire, A., McMurray, J.J., Cost of an emerging epidemic: an economic analysis of atrial fibrillation in the UK. [published correction appears in Heart. 2007;93(11):1472. Murphy N [corrected to Murphy NF]] Heart 90:3 (2004), 286–292.
93. 93 Kim, M.H., Johnston, S.S., Chu, B.C., Dalal, M.R., Schulman, K.L., Estimation of total incremental health care costs in patients with atrial fibrillation in the United States. Circ Cardiovasc Qual Outcomes 4:3 (2011), 313–320.
94. 94 Lee, W.C., Lamas, G.A., Balu, S., Spalding, J., Wang, Q., Pashos, C.L., Direct treatment cost of atrial fibrillation in the elderly American population: a Medicare perspective. J Med Econ 11:2 (2008), 281–298.
95. 95 Brüggenjürgen, B., Rossnagel, K., Roll, S., et al. The impact of atrial fibrillation on the cost of stroke: the berlin acute stroke study. Value Health 10:2 (2007), 137–143.
96. 96 Blomstrom Lundqvist, C., Lip, G.Y., Kirchhof, P., What are the costs of atrial fibrillation?. Europace 13:suppl 2 (2011), ii9–ii12.
97. 97 Sheikh, A., Patel, N.J., Nalluri, N., et al. Trends in hospitalization for atrial fibrillation: epidemiology, cost, and implications for the future. Prog Cardiovasc Dis 58:2 (2015), 105–116.
98. 98 January, C.T., Wann, L.S., Alpert, J.S., et al., American College of Cardiology/American Heart Association Task Force on Practice Guidelines. 2014 AHA/ACC/HRS guideline for the management of patients with atrial fibrillation: a report of the American College of Cardiology/American Heart Association Task Force on Practice Guidelines and the Heart Rhythm Society. [published correction appears in J Am Coll Cardiol. 2014;64(21):2305-2307] J Am Coll Cardiol 64:21 (2014), e1–e76.
99. 99 Everett, T.H., Olgin, J.E., Atrial fibrosis and the mechanisms of atrial fibrillation. Heart Rhythm 4:3 suppl (2007), S24–S27.
100. 100 Wakili, R., Voigt, N., Kääb, S., Dobrev, D., Nattel, S., Recent advances in the molecular pathophysiology of atrial fibrillation. J Clin Invest 121:8 (2011), 2955–2968.
101. 101 Sanders, P., Morton, J.B., Davidson, N.C., et al. Electrical remodeling of the atria in congestive heart failure: electrophysiological and electroanatomic mapping in humans. Circulation 108:12 (2003), 1461–1468.
102. 102 Allessie, M., Ausma, J., Schotten, U., Electrical, contractile and structural remodeling during atrial fibrillation. Cardiovasc Res 54:2 (2002), 230–246.
103. 103 Burstein, B., Nattel, S., Atrial fibrosis: mechanisms and clinical relevance in atrial fibrillation. J Am Coll Cardiol 51:8 (2008), 802–809.
104. 104 Moe, G.K., Rheinboldt, W.C., Abildskov, J., A computer model of atrial fibrillation. Am Heart J 67:2 (1964), 200–220.
105. 105 Valderrábano, M., Atrial fibrillation: the mother rotor and its rebellious offspring take turns sustaining the family. Heart Rhythm 6:7 (2009), 1018–1019.
106. 106 Narayan, S.M., Krummen, D.E., Shivkumar, K., Clopton, P., Rappel, W.J., Miller, J.M., Treatment of atrial fibrillation by the ablation of localized sources: CONFIRM (Conventional Ablation for Atrial Fibrillation with or Without Focal Impulse and Rotor Modulation) trial. J Am Coll Cardiol 60:7 (2012), 628–636.
107. 107 Verheule, S., Wilson, E., Everett, T. IVth, Shanbhag, S., Golden, C., Olgin, J., Alterations in atrial electrophysiology and tissue structure in a canine model of chronic atrial dilatation due to mitral regurgitation. Circulation 107:20 (2003), 2615–2622.
108. 108 Healey, J.S., Connolly, S.J., Atrial fibrillation: hypertension as a causative agent, risk factor for complications, and potential therapeutic target. Am J Cardiol 91:10A (2003), 9G–14G.
109. 109 Li, D., Melnyk, P., Feng, J., et al. Effects of experimental heart failure on atrial cellular and ionic electrophysiology. Circulation 101:22 (2000), 2631–2638.
110. 110 Ohtani, K., Yutani, C., Nagata, S., Koretsune, Y., Hori, M., Kamada, T., High prevalence of atrial fibrosis in patients with dilated cardiomyopathy. J Am Coll Cardiol 25:5 (1995), 1162–1169.
111. 111 Reil, J.C., Hohl, M., Selejan, S., et al. Aldosterone promotes atrial fibrillation. Eur Heart J 33:16 (2012), 2098–2108.
112. 112 Li, D., Shinagawa, K., Pang, L., et al. Effects of angiotensin-converting enzyme inhibition on the development of the atrial fibrillation substrate in dogs with ventricular tachypacing-induced congestive heart failure. Circulation 104:21 (2001), 2608–2614.
113. 113 Vermes, E., Tardif, J.C., Bourassa, M.G., et al. Enalapril decreases the incidence of atrial fibrillation in patients with left ventricular dysfunction: insight from the Studies Of Left Ventricular Dysfunction (SOLVD) trials. Circulation 107:23 (2003), 2926–2931.
114. 114 Nattel, S., Dobrev, D., The multidimensional role of calcium in atrial fibrillation pathophysiology: mechanistic insights and therapeutic opportunities. Eur Heart J 33:15 (2012), 1870–1877.
115. 115 Singh, B., Atrial fibrillation: from ion channels to bedside treatment options. J Electrocardiol 42:6 (2009), 660–670.
116. 116 Boos, C.J., Anderson, R.A., Lip, G.Y., Is atrial fibrillation an inflammatory disorder?. Eur Heart J 27:2 (2006), 136–149.
117. 117 Chung, M.K., Martin, D.O., Sprecher, D., et al. C-reactive protein elevation in patients with atrial arrhythmias: inflammatory mechanisms and persistence of atrial fibrillation. Circulation 104:24 (2001), 2886–2891.
118. 118 Dernellis, J., Panaretou, M., C-reactive protein and paroxysmal atrial fibrillation: evidence of the implication of an inflammatory process in paroxysmal atrial fibrillation. Acta Cardiol 56:6 (2001), 375–380.
119. 119 Asselbergs, F.W., van den Berg, M.P., Diercks, G.F.H., van Gilst, W.H., van Veldhuisen, D.J., C-reactive protein and microalbuminuria are associated with atrial fibrillation. Int J Cardiol 98:1 (2005), 73–77.
120. 120 McElderry, H.T., McGiffin, D.C., Plumb, V.J., et al. Proarrhythmic aspects of atrial fibrillation surgery: mechanisms of postoperative macroreentrant tachycardias. Circulation 117:2 (2008), 155–162.
121. 121 Anderson, J.L., Allen Maycock, C.A., Lappé, D.L., et al., Intermountain Heart Collaborative Study Group. Frequency of elevation of C-reactive protein in atrial fibrillation. Am J Cardiol 94:10 (2004), 1255–1259.
122. 122 Conway, D.S., Buggins, P., Hughes, E., Lip, G.Y., Predictive value of indexes of inflammation and hypercoagulability on success of cardioversion of persistent atrial fibrillation. Am J Cardiol 94:4 (2004), 508–510.
123. 123 Kistler, P.M., Sanders, P., Fynn, S.P., et al. Electrophysiologic and electroanatomic changes in the human atrium associated with age. J Am Coll Cardiol 44:1 (2004), 109–116.
124. 124 Bettoni, M., Zimmermann, M., Autonomic tone variations before the onset of paroxysmal atrial fibrillation. Circulation 105:23 (2002), 2753–2759.
125. 125 Chen, P.S., Chen, L.S., Fishbein, M.C., Lin, S.F., Nattel, S., Role of the autonomic nervous system in atrial fibrillation: pathophysiology and therapy. Circ Res 114:9 (2014), 1500–1515.
126. 126 Nguyen, B.L., Fishbein, M.C., Chen, L.S., Chen, P.S., Masroor, S., Histopathological substrate for chronic atrial fibrillation in humans. Heart Rhythm 6:4 (2009), 454–460.
127. 127 Sharifov, O.F., Fedorov, V.V., Beloshapko, G.G., Glukhov, A.V., Yushmanova, A.V., Rosenshtraukh, L.V., Roles of adrenergic and cholinergic stimulation in spontaneous atrial fibrillation in dogs. J Am Coll Cardiol 43:3 (2004), 483–490.
128. 128 Shinbane, J.S., Wood, M.A., Jensen, D.N., Ellenbogen, K.A., Fitzpatrick, A.P., Scheinman, M.M., Tachycardia-induced cardiomyopathy: a review of animal models and clinical studies. J Am Coll Cardiol 29:4 (1997), 709–715.
129. 129 Van Gelder, I.C., Groenveld, H.F., Crijns, H.J., et al., RACE II Investigators. Lenient versus strict rate control in patients with atrial fibrillation. N Engl J Med 362:15 (2010), 1363–1373.
130. 130 Lee, A.M., Melby, S.J., Damiano, R.J. Jr., The surgical treatment of atrial fibrillation. Surg Clin North Am 89:4 (2009), 1001–1020 x-xi.
131. 131 Calkins, H., Brugada, J., Packer, D.L., et al., Heart Rhythm Society; European Heart Rhythm Association; European Cardiac Arrhythmia Society; American College of Cardiology; American Heart Association; Society of Thoracic Surgeons. HRS/EHRA/ECAS expert consensus statement on catheter and surgical ablation of atrial fibrillation: recommendations for personnel, policy, procedures and follow-up. A report of the Heart Rhythm Society (HRS) Task Force on Catheter and Surgical Ablation of Atrial Fibrillation developed in partnership with the EuropeanHeart Rhythm Association (EHRA) and the European Cardiac Arrhythmia Society (ECAS); in collaboration with the American College of Cardiology (ACC), American Heart Association (AHA), and the Society of Thoracic Surgeons (STS). Endorsed and approved by the governing bodies of the American College of Cardiology, the American Heart Association, the European Cardiac Arrhythmia Society, the European Heart RhythmAssociation, the Society of Thoracic Surgeons, and the Heart Rhythm Society. [published correction appears in Europace. 2009;11(1):132] Europace 9:6 (2007), 335–379.
132. 132 Waldo, A.L., Rate control versus rhythm control in atrial fibrillation: lessons learned from clinical trials of atrial fibrillation. Prog Cardiovasc Dis 58:2 (2015), 168–176.
133. 133 Van Gelder, I.C., Hagens, V.E., Bosker, H.A., et al., Rate Control versus Electrical Cardioversion for Persistent Atrial Fibrillation Study Group. A comparison of rate control and rhythm control in patients with recurrent persistent atrial fibrillation. N Engl J Med 347:23 (2002), 1834–1840.
134. 134 Corley, S.D., Epstein, A.E., DiMarco, J.P., et al., AFFIRM Investigators. Relationships between sinus rhythm, treatment, and survival in the Atrial Fibrillation Follow-Up Investigation of Rhythm Management (AFFIRM) Study. Circulation 109:12 (2004), 1509–1513.
135. 135 Roy, D., Talajic, M., Nattel, S., et al., Atrial Fibrillation and Congestive Heart Failure Investigators. Rhythm control versus rate control for atrial fibrillation and heart failure. N Engl J Med 358:25 (2008), 2667–2677.
136. 136 Gillinov, A.M., Bagiella, E., Moskowitz, A.J., et al., CTSN. Rate control versus rhythm control for atrial fibrillation after cardiac surgery. N Engl J Med 374:20 (2016), 1911–1921.
137. 137 Hagens, V.E., Ranchor, A.V., Van Sonderen, E., et al., RACE Study Group. Effect of rate or rhythm control on quality of life in persistent atrial fibrillation: results from the Rate Control Versus Electrical Cardioversion (RACE) study. J Am Coll Cardiol 43:2 (2004), 241–247.
138. 138 Jones, D.G., Haldar, S.K., Hussain, W., et al. A randomized trial to assess catheter ablation versus rate control in the management of persistent atrial fibrillation in heart failure. J Am Coll Cardiol 61:18 (2013), 1894–1903.
139. 139 Lafuente-Lafuente, C., Valembois, L., Bergmann, J.F., Belmin, J., Antiarrhythmics for maintaining sinus rhythm after cardioversion of atrial fibrillation. Cochrane Database Syst Rev, 28(3), 2015, CD005049.
140. 140 Freemantle, N., Lafuente-Lafuente, C., Mitchell, S., Eckert, L., Reynolds, M., Mixed treatment comparison of dronedarone, amiodarone, sotalol, flecainide, and propafenone, for the management of atrial fibrillation. Europace 13:3 (2011), 329–345.
141. 141 Zimetbaum, P., Antiarrhythmic drug therapy for atrial fibrillation. Circulation 125:2 (2012), 381–389.
142. 142 Bellandi, F., Simonetti, I., Leoncini, M., et al. Long-term efficacy and safety of propafenone and sotalol for the maintenance of sinus rhythm after conversion of recurrent symptomatic atrial fibrillation. Am J Cardiol 88:6 (2001), 640–645.
143. 143 Dogan, A., Ergene, O., Nazli, C., et al. Efficacy of propafenone for maintaining sinus rhythm in patients with recent onset or persistent atrial fibrillation after conversion: A randomized, placebo-controlled study. Acta Cardiol 59:3 (2004), 255–261.
144. 144 Benditt, D.G., Williams, J.H., Jin, J., et al. Maintenance of sinus rhythm with oral d,l-sotalol therapy in patients with symptomatic atrial fibrillation and/or atrial flutter. Am J Cardiol 84:3 (1999), 270–277.
145. 145 Singh, S., Zoble, R.G., Yellen, L., et al. Efficacy and safety of oral dofetilide in converting to and maintaining sinus rhythm in patients with chronic atrial fibrillation or atrial flutter: the Symptomatic Atrial Fibrillation Investigative Research on Dofetilide (SAFIRE-D) study. Circulation 102:19 (2000), 2385–2390.
146. 146 Pedersen, O.D., Bagger, H., Keller, N., Marchant, B., Køber, L., Torp-Pedersen, C., Efficacy of dofetilide in the treatment of atrial fibrillation-flutter in patients with reduced left ventricular function: a Danish Investigations of Arrhythmia and Mortality ON Dofetilide (DIAMOND) substudy. Circulation 104:3 (2001), 292–296.
147. 147 Connolly, S.J., Camm, A.J., Halperin, J.L., et al., PALLAS Investigators. Dronedarone in high-risk permanent atrial fibrillation. [published correction appears in N Engl J Med. 201216;366(7):672] N Engl J Med 365:24 (2011), 2268–2276.
148. 148 Køber, L., Torp-Pedersen, C., McMurray, J.J., et al., Dronedarone Study Group. Increased mortality after dronedarone therapy for severe heart failure. [published correction appears in N Engl J Med. 2010;363(14):1384] N Engl J Med 358:25 (2008), 2678–2687.
149. 149 Hohnloser, S.H., Crijns, H.J., van Eickels, M., et al., ATHENA Investigators. Effect of dronedarone on cardiovascular events in atrial fibrillation. [published corrections appear in N Engl J Med. 2009;360(23):2487 and N Engl J Med. 2011;364(15):1481] N Engl J Med 360:7 (2009), 668–678.
150. 150 Singh, B.N., Connolly, S.J., Crijns, H.J., et al., EURIDIS and ADONIS Investigators. Dronedarone for maintenance of sinus rhythm in atrial fibrillation or flutter. N Engl J Med 357:10 (2007), 987–999.
151. 151 Touboul, P., Brugada, J., Capucci, A., Crijns, H.J., Edvardsson, N., Hohnloser, S.H., Dronedarone for prevention of atrial fibrillation: a dose-ranging study. Eur Heart J 24:16 (2003), 1481–1487.
152. 152 Wolf, P.A., Abbott, R.D., Kannel, W.B., Atrial fibrillation as an independent risk factor for stroke: the Framingham Study. Stroke 22:8 (1991), 983–988.
153. 153 Lin, H.J., Wolf, P.A., Kelly-Hayes, M., et al. Stroke severity in atrial fibrillation: the Framingham Study. Stroke 27:10 (1996), 1760–1764.
154. 154 Lip, G.Y., Nieuwlaat, R., Pisters, R., Lane, D.A., Crijns, H.J., Refining clinical risk stratification for predicting stroke and thromboembolism in atrial fibrillation using a novel risk factor-based approach: the Euro Heart Survey on atrial fibrillation. Chest 137:2 (2010), 263–272.
155. 155 Pisters, R., Lane, D.A., Nieuwlaat, R., de Vos, C.B., Crijns, H.J., Lip, G.Y., A novel user-friendly score (HAS-BLED) to assest 1-year risk of major bleeding in patients with atrial fibrillation: the Euro Heart Survey. Chest 138:5 (2010), 1093–1100.
156. 156 Medi, C., Hankey, G.J., Freedman, S.B., Stroke risk and antithrombotic strategies in atrial fibrillation. Stroke 41:11 (2010), 2705–2713.
157. 157 Olesen, J.B., Lip, G.Y., Kamper, A.L., et al. Stroke and bleeding in atrial fibrillation with chronic kidney disease. [published correction appears in N Engl J Med. 2012;367(23):2262] N Engl J Med 367:7 (2012), 625–635.
158. 158 Kwon, Y., Norby, F.L., Jensen, P.N., et al. Association of smoking, alcohol, and obesity with cardiovascular death and ischemic stroke in atrial fibrillation: the Atherosclerosis Risk in Communities (ARIC) study and Cardiovascular Health Study (CHS). PLoS One, 11(1), 2016, e0147065.
159. 159 Healey, J.S., Connolly, S.J., Gold, M.R., et al., ASSERT Investigators. Subclinical atrial fibrillation and the risk of stroke. N Engl J Med 366:2 (2012), 120–129.
160. 160 Di Biase, L., Santangeli, P., Anselmino, M., et al. Does the left atrial appendage morphology correlate with the risk of stroke in patients with atrial fibrillation? Results from a multicenter study. J Am Coll Cardiol 60:6 (2012), 531–538.
161. 161 Aguilar, M., Hart, R., Antiplatelet therapy for preventing stroke in patients with non-valvular atrial fibrillation and no previous history of stroke or transient ischemic attacks. Cochrane Database Syst Rev(4), 2005, CD001925.
162. 162 Hart, R.G., Pearce, L.A., Aguilar, M.I., Meta-analysis: antithrombotic therapy to prevent stroke in patients who have nonvalvular atrial fibrillation. Ann Intern Med 146:12 (2007), 857–867.
163. 163 ACTIVE Investigators, Connolly, S.J., Pogue, J., Hart, R.G., et al. Effect of clopidogrel added to aspirin in patients with atrial fibrillation. N Engl J Med 360:20 (2009), 2066–2078.
164. 164 ACTIVE Writing Group of the ACTIVE Investigators, Connolly, S., Pogue, J., Hart, R., et al. Clopidogrel plus aspirin versus oral anticoagulation for atrial fibrillation in the Atrial fibrillation Clopidogrel Trial with Irbesartan for prevention of Vascular Events (ACTIVE W): a randomised controlled trial. Lancet 367:9526 (2006), 1903–1912.
165. 165 Connolly, S.J., Ezekowitz, M.D., Yusuf, S., et al., RE-LY Steering Committee and Investigators. Dabigatran versus warfarin in patients with atrial fibrillation. [published correction appears in N Engl J Med. 2010;363(19):1877] N Engl J Med 361:12 (2009), 1139–1151.
166. 166 Patel, M.R., Mahaffey, K.W., Garg, J., et al., ROCKET AF Investigators. Rivaroxaban versus warfarin in nonvalvular atrial fibrillation. N Engl J Med 365:10 (2011), 883–891.
167. 167 Granger, C., Alexander, J.H., McMurray, J.J., et al., ARISTOTLE Committees and Investigators. Apixaban versus warfarin in atrial fibrillation. N Engl J Med 365:11 (2011), 981–992.
168. 168 Giugliano, R.P., Ruff, C.T., Braunwald, E., et al., ENGAGE AF-TIMI 48 Investigators. Edoxaban versus warfarin in patients with atrial fibrillation. N Engl J Med 369:22 (2013), 2093–2104.
169. 169 Pollack, C.V. Jr., Reilly, P.A., Eikelboom, J., et al. Idarucizumab for dabigatran reversal. N Engl J Med 373:6 (2015), 511–520.
170. 170 Eikelboom, J.W., Connolly, S.J., Brueckmann, M., et al., RE-ALIGN Investigators. Dabigatran versus warfarin in patients with mechanical heart valves. N Engl J Med 369:13 (2013), 1206–1214.
171. 171 Blackshear, J.L., Odell, J.A., Appendage obliteration to reduce stroke in cardiac surgical patients with atrial fibrillation. Ann Thorac Surg 61:2 (1996), 755–759.
172. 172 Al-Saady, N.M., Obel, O.A., Camm, A.J., Left atrial appendage: structure, function, and role in thromboembolism. Heart 82:5 (1999), 547–554.
173. 173 La Meir, M., Gelsomino, S., Lucà, F., et al. Minimal invasive surgery for atrial fibrillation: an updated review. Europace 15:2 (2013), 170–182.
174. 174 Kanderian, A.S., Gillinov, A.M., Pettersson, G.B., Blackstone, E., Klein, A.L., Success of surgical left atrial appendage closure: assessment by transesophageal echocardiography. J Am Coll Cardiol 52:11 (2008), 924–929.
175. 175 Ohtsuka, T., Ninomiya, M., Nonaka, T., Hisagi, M., Ota, T., Mizutani, T., Thoracoscopic stand-alone left atrial appendectomy for thromboembolism prevention in nonvalvular atrial fibrillation. J Am Coll Cardiol 62:2 (2013), 103–107.
176. 176 Ailawadi, G., Gerdisch, M.W., Harvey, R.L., et al. Exclusion of the left atrial appendage with a novel device: early results of a multicenter trial. J Thorac Cardiovasc Surg 142:5 (2011), 1002–1009 1009e1.
177. 177 Lin, A.C., Knight, B.P., Left atrial appendage closure. Prog Cardiovasc Dis 58:2 (2015), 195–201.
178. 178 Fountain, R.B., Holmes, D.R., Chandrasekaran, K., et al. The PROTECT AF (WATCHMAN Left Atrial Appendage System for Embolic PROTECTion in Patients with Atrial Fibrillation) Trial. Am Heart J 151:5 (2006), 956–961.
179. 179 Reddy, V.Y., Doshi, S.K., Sievert, H., et al., PROTECT AF Investigators. Percutaneous left atrial appendage closure for stroke prophylaxis in patients with atrial fibrillation: 2.3-year follow-up of the PROTECT AF (Watchman Left Atrial Appendage System for Embolic Protection in Patients with Atrial Fibrillation) trial. Circulation 127:6 (2013), 720–729.
180. 180 Reddy, V.Y., Holmes, D., Doshi, S.K., Neuzil, P., Kar, S., Safety of percutaneous left atrial appendage closure: results from the Watchman Left Atrial Appendage System for Embolic Protection in Patients with AF (PROTECT AF) clinical trial and the Continued Access Registry. Circulation 123:4 (2011), 417–424.
181. 181 Holmes, D.R. Jr., Lakkireddy, D.R., Whitlock, R.P., Waksman, R., Mack, M.J., Left atrial appendage occlusion: opportunities and challenges. J Am Coll Cardiol 63:4 (2014), 291–298.
182. 182 Holmes, D.R. Jr., Kar, S., Price, M.J., et al. Prospective randomized evaluation of the Watchman left atrial appendage closure device in patients with atrial fibrillation versus long-term warfarin therapy: the PREVAIL trial. [published correction appears in J Am Coll Cardiol. 2014;64(11):1186] J Am Coll Cardiol 64:1 (2014), 1–12.
183. 183 Boersma, L.V.A., Schmidt, B., Betts, T.R., et al., EWOLUTION Investigators. Implant success and safety of left atrial appendage closure with the WATCHMAN device: peri-procedural outcomes from the EWOLUTION registry. Eur Heart J 37:31 (2016), 2465–2474.
184. 184 Reddy, V.Y., Möbius-Winkler, S., Miller, M.A., et al. Left atrial appendage closure with the Watchman device in patients with a contraindication for oral anticoagulation: the ASAP study (ASA Plavix Feasibility Study With Watchman Left Atrial Appendage Closure Technology). J Am Coll Cardiol 61:25 (2013), 2551–2556.
185. 185 Reddy, V.Y., Akehurst, R.L., Armstrong, S.O., et al. Cost effectiveness of left atrial appendage closure with the Watchman device for atrial fibrillation patients with absolute contraindications to warfarin. Europace 18:7 (2016), 979–986.
186. 186 Price, M.J., Gibson, D.N., Yakubov, S.J., et al. Early safety and efficacy of percutaneous left atrial appendage suture ligation: results from the U.S. transcatheter LAA ligation consortium. J Am Coll Cardiol 64:6 (2014), 565–572.
187. 187 Chatterjee, S., Herrmann, H.C., Wilensky, R.L., et al. Safety and procedural success of left atrial appendage exclusion with the Lariat device: a systematic review of published reports and analytic review of the FDA MAUDE database. JAMA Intern Med 175:7 (2015), 1104–1109.
188. 188 Pillarisetti, J., Reddy, Y.M., Gunda, S., et al. Endocardial (Watchman) vs epicardial (Lariat) left atrial appendage exclusion devices: understanding the differences in the location and type of leaks and their clinical implications. Heart Rhythm 12:7 (2015), 1501–1507.
189. 189 Lakkireddy, D., Afzal, M.R., Lee, R.J., et al. Short and long-term outcomes of percutaneous left atrial appendage suture ligation: results from a US multicenter evaluation. Heart Rhythm 13:5 (2016), 1030–1036.
190. 190 Calkins, H., Kuck, K.H., Cappato, R., et al., Heart Rhythm Society Task Force on Catheter and Surgical Ablation of Atrial Fibrillation. 2012 HRS/EHRA/ECAS expert consensus statement on catheter and surgical ablation of atrial fibrillation: recommendations for patient selection, procedural techniques, patient management and follow-up, definitions, endpoints, and research trial design: a report of the Heart Rhythm Society (HRS) Task Force on Catheter and Surgical Ablation of Atrial Fibrillation. Developed in partnership with the European Heart Rhythm Association (EHRA), a registered branch of the European Society of Cardiology (ESC) and the European Cardiac Arrhythmia Society (ECAS); and in collaboration with the American College of Cardiology (ACC), American Heart Association (AHA), the Asia Pacific Heart Rhythm Society (APHRS), and the Society of Thoracic Surgeons (STS). Endorsed by the governing bodies of the American College of Cardiology Foundation, the American Heart Association, the European Cardiac Arrhythmia Society, the European Heart RhythmAssociation, the Society of Thoracic Surgeons, the Asia Pacific Heart Rhythm Society, and the Heart Rhythm Society. Heart Rhythm 9:4 (2012), 632–696e21.
191. 191 Haïssaguerre, M., Jaïs, P., Shah, D.C., et al. Spontaneous initiation of atrial fibrillation by ectopic beats originating in the pulmonary veins. N Engl J Med 339:10 (1998), 659–666.
192. 192 Wazni, O.M., Marrouche, N.F., Martin, D.O., et al. Radiofrequency ablation vs antiarrhythmic drugs as first-line treatment of symptomatic atrial fibrillation: a randomized trial. JAMA 293:21 (2005), 2634–2640.
193. 193 Pappone, C., Augello, G., Sala, S., et al. A randomized trial of circumferential pulmonary vein ablation versus antiarrhythmic drug therapy in paroxysmal atrial fibrillation: the APAF Study. J Am Coll Cardiol 48:11 (2006), 2340–2347.
194. 194 Jaïs, P., Cauchemez, B., Macle, L., et al. Catheter ablation versus antiarrhythmic drugs for atrial fibrillation: the A4 study. [published correction appears in Circulation. 2009;120(10):e83] Circulation 118:24 (2008), 2498–2505.
195. 195 Wilber, D.J., Pappone, C., Neuzil, P., et al., ThermoCool AF Trial Investigators. Comparison of antiarrhythmic drug therapy and radiofrequency catheter ablation in patients with paroxysmal atrial fibrillation: a randomized controlled trial. JAMA 303:4 (2010), 333–340.
196. 196 Parkash, R., Tang, A.S., Sapp, J.L., Wells, G., Approach to the catheter ablation technique of paroxysmal and persistent atrial fibrillation: a meta-analysis of the randomized controlled trials. J Cardiovasc Electrophysiol 22:7 (2011), 729–738.
197. 197 Ganesan, A.N., Shipp, N.J., Brooks, A.G., et al. Long-term outcomes of catheter ablation of atrial fibrillation: a systematic review and meta-analysis. J Am Heart Assoc, 2(2), 2013, e004549.
198. 198 Nattel, S., Burstein, B., Dobrev, D., Atrial remodeling and atrial fibrillation: mechanisms and implications. Circ Arrhythm Electrophysiol 1:1 (2008), 62–73.
199. 199 Tung, R., Buch, E., Shivkumar, K., Catheter ablation of atrial fibrillation. Circulation 126:2 (2012), 223–229.
200. 200 Krittayaphong, R., Raungrattanaamporn, O., Bhuripanyo, K., Sriratanasathavorn, C., Pooranawattanakul, S., Punlee, K., Kangkagate, C., A randomized clinical trial of the efficacy of radiofrequency catheter ablation and amiodarone in the treatment of symptomatic atrial fibrillation. J Med Assoc Thai 86:Suppl 1 (2003 May), S8–S16.
201. 201 Stabile, G., Bertaglia, E., Senatore, G., et al. Catheter ablation treatment in patients with drug-refractory atrial fibrillation: a prospective, multi-centre, randomized, controlled study (Catheter Ablation For The Cure Of Atrial Fibrillation Study). Eur Heart J 27:2 (2006 Jan), 216–221.
202. 202 Oral, H., Pappone, C., Chugh, A., et al. Circumferential pulmonary-vein ablation for chronic atrial fibrillation. N Engl J Med 354:9 (2006 Mar 2), 934–941.
203. 203 Forleo, G.B., Mantica, M., De Luca, L., et al. Catheter ablation of atrial fibrillation in patients with diabetes mellitus type 2: results from a randomized study comparing pulmonary vein isolation versus antiarrhythmic drug therapy. J Cardiovasc Electrophysiol 20:1 (2009 Jan), 22–28.
204. 204 Packer, D.L., Kowal, R.C., Wheelan, K.R., Cryoballoon ablation of pulmonary veins for paroxysmal atrial fibrillation: first results of the North American Arctic Front (STOP AF) pivotal trial. J Am Coll Cardiol 61:16 (2013 Apr 23), 1713–1723.
205. 205 Cosedis Nielsen, J., Johannessen, A., Raatikainen, P., et al. Radiofrequency ablation as initial therapy in paroxysmal atrial fibrillation. N Engl J Med 367:17 (2012 Oct 25), 1587–1595.
206. 206 Morillo, C.A., Verma, A., Connolly, S.J., et al. Radiofrequency ablation vs antiarrhythmic drugs as first-line treatment of paroxysmal atrial fibrillation (RAAFT-2): a randomized trial. JAMA 311:7 (2014 Feb 19), 692–700.
207. 207 Mont, L., Bisbal, F., Hernández-Madrid, A., et al. Catheter ablation vs. antiarrhythmic drug treatment of persistent atrial fibrillation: a multicentre, randomized, controlled trial (SARA study). Eur Heart J 35:8 (2014 Feb), 501–507.
208. 208 Moreno, J., Zamorano, J.L., The CABANA trial. Eur Heart J 35:29 (2014), 1908–1909.
209. 209 Aliot, E., Brandes, A., Eckardt, L., et al. The EAST study: redefining the role of rhythm control therapy in atrial fibrillation: EAST, the Early treatment of Atrial fibrillation for Stroke prevention Trial. Eur Heart J 36:5 (2015), 255–256.
210. 210 Walters, T.E., Ellims, A.H., Kalman, J.M., The role of left atrial imaging in the management of atrial fibrillation. Prog Cardiovasc Dis 58:2 (2015), 136–151.
211. 211 Mahida, S., Hooks, D.A., Nentwich, K., et al. nMARQ ablation for atrial fibrillation: results from a multicenter study. J Cardiovasc Electrophysiol 26:7 (2015), 724–729.
212. 212 Natale, A., Reddy, V.Y., Monir, G., et al. Paroxysmal AF catheter ablation with a contact force sensing catheter: results of the prospective, multicenter SMART-AF trial. J Am Coll Cardiol 64:7 (2014), 647–656.
213. 213 Reddy, V.Y., Dukkipati, S.R., Neuzil, P., et al. Randomized, controlled trial of the safety and effectiveness of a contact force-sensing irrigated catheter for ablation of paroxysmal atrial fibrillation: results of the TactiCath Contact Force Ablation Catheter Study for Atrial Fibrillation (TOCCASTAR) study. Circulation 132:10 (2015), 907–915.
214. 214 Tang, M., Kriatselis, C., Nedios, S., et al. A novel cryoballoon technique for mapping and isolating pulmonary veins: a feasibility and efficacy study. J Cardiovasc Electrophysiol 21:6 (2010), 626–631.
215. 215 Packer, D.L., Kowal, R.C., Wheelan, K.R., et al., STOP AF Cryoablation Investigators. Cryoballoon ablation of pulmonary veins for paroxysmal atrial fibrillation: first results of the North American Arctic Front (STOP AF) pivotal trial. J Am Coll Cardiol 61:16 (2013), 1713–1723.
216. 216 Luik, A., Radzewitz, A., Kieser, M., et al. Cryoballoon versus open irrigated radiofrequency ablation in patients with paroxysmal atrial fibrillation: the prospective, randomized, controlled, noninferiority FreezeAF study. Circulation 132:14 (2015), 1311–1319.
217. 217 Kuck, K.H., Brugada, J., Fürnkranz, A., et al., FIRE and ICE Investigators. Cryoballoon or radiofrequency ablation for paroxysmal atrial fibrillation. N Engl J Med 374:23 (2016), 2235–2245.
218. 218 Dukkipati, S.R., Kuck, K.H., Neuzil, P., et al. Pulmonary vein isolation using a visually guided laser balloon catheter: the first 200-patient multicenter clinical experience. Circ Arrhythm Electrophysiol 6:3 (2013), 467–472.
219. 219 Nishida, K., Datino, T., Macle, L., Nattel, S., Atrial fibrillation ablation: translating basic mechanistic insights to the patient. J Am Coll Cardiol 64:8 (2014), 823–831.
220. 220 Jiang, R.H., Po, S.S., Tung, R., et al. Incidence of pulmonary vein conduction recovery in patients without clinical recurrence after ablation of paroxysmal atrial fibrillation: mechanistic implications. Heart Rhythm 11:6 (2014), 969–976.
221. 221 Sehra, R., Narayan, S.M., Hummel, J., Thinking outside the box: Rotor modulation in the treatment of atrial fibrillation. J Atr Fibrillation 6 (2013), 90–95.
222. 222 Gehi, AK, Mounsey, JP, Pursell, I, et al. Hybrid epicardial-endocardial ablation using a pericardioscopic technique for the treatment of atrial fibrillation. Heart Rhythm 10:1 (2013), 22–28.
223. 223 Robinson MD, Chiravuri M, McPherson C, Winslow R. Maximizing ablation, limiting invasiveness, and being realistic about atrial fibrillation: The convergent hybrid ablation procedure for advanced AF. 2013;13(6).
224. 224 Jaïs, P., Hocini, M., Hsu, L.F., et al. Technique and results of linear ablation at the mitral isthmus. Circulation 110:19 (2004), 2996–3002.
225. 225 Hocini, M., Jaïs, P., Sanders, P., et al. Techniques, evaluation, and consequences of linear block at the left atrial roof in paroxysmal atrial fibrillation: a prospective randomized study. Circulation 112:24 (2005), 3688–3696.
226. 226 Nademanee, K., McKenzie, J., Kosar, E., et al. A new approach for catheter ablation of atrial fibrillation: mapping of the electrophysiologic substrate. J Am Coll Cardiol 43:11 (2004), 2044–2053.
227. 227 Verma, A., Jiang, C.Y., Betts, T.R., et al., STAR AF II Investigators. Approaches to catheter ablation for persistent atrial fibrillation. N Engl J Med 372:19 (2015), 1812–1822.
228. 228 Sawhney, N., Anousheh, R., Chen, W., Feld, G.K., Circumferential pulmonary vein ablation with additional linear ablation results in an increased incidence of left atrial flutter compared with segmental pulmonary vein isolation as an initial approach to ablation of paroxysmal atrial fibrillation. Circ Arrhythm Electrophysiol 3:3 (2010), 243–248.
229. 229 Oral, H., Chugh, A., Yoshida, K., et al. A randomized assessment of the incremental role of ablation of complex fractionated atrial electrograms after antral pulmonary vein isolation for long-lasting persistent atrial fibrillation. J Am Coll Cardiol 53:9 (2009), 782–789.
230. 230 Pandit, S.V., Jalife, J., Rotors and the dynamics of cardiac fibrillation. Circ Res 112:5 (2013), 849–862.
231. 231 Miller, J.M., Kowal, R.C., Swarup, V., et al. Initial independent outcomes from focal impulse and rotor modulation ablation for atrial fibrillation: multicenter FIRM registry. J Cardiovasc Electrophysiol 25:9 (2014), 921–929.
232. 232 Dubois, R., Shah, A.J., Hocini, M., et al. Non-invasive cardiac mapping in clinical practice: Application to the ablation of cardiac arrhythmias. J Electrocardiol 48:6 (2015), 966–974.
233. 233 Lim, H.S., Zellerhoff, S., Derval, N., et al. Noninvasive mapping to guide atrial fibrillation ablation. Card Electrophysiol Clin 7:1 (2015), 89–98.
234. 234 Nattel, S., Harada, M., Atrial remodeling and atrial fibrillation: recent advances and translational perspectives. J Am Coll Cardiol 63:22 (2014), 2335–2345.
235. 235 Gal, P., Marrouche, N.F., Magnetic resonance imaging of atrial fibrosis: redefining atrial fibrillation to a syndrome. [published online ahead of print] Eur Heart J, September 25, 2015 doi: 10.1093/eurheartj/ehv514.
236. 236 Marrouche, N.F., Wilber, D., Hindricks, G., et al. Association of atrial tissue fibrosis identified by delayed enhancement MRI and atrial fibrillation catheter ablation: the DECAAF study. [published correction appears in JAMA. 2014;312(17):1805] JAMA 311:5 (2014), 498–506.
237. 237 Higuchi, K., Akkaya, M., Akoum, N., Marrouche, N.F., Cardiac MRI assessment of atrial fibrosis in atrial fibrillation: implications for diagnosis and therapy. Heart 100:7 (2014), 590–596.
238. 238 Lawrance, C.P., Henn, M.C., Damiano, R.J. Jr., Surgical ablation for atrial fibrillation: techniques, indications, and results. Curr Opin Cardiol 30:1 (2015), 58–64.
239. 239 Kumar, P., Kiser, A.C., Gehi, A.K., Hybrid treatment of atrial fibrillation. Prog Cardiovasc Dis 58:2 (2015), 213–220.
240. 240 Pison, L., La Meir, M., van Opstal, J., Blaauw, Y., Maessen, J., Crijns, H.J., Hybrid thoracoscopic surgical and transvenous catheter ablation of atrial fibrillation. J Am Coll Cardiol 60:1 (2012), 54–61.
241. 241 Bulava, A., Mokracek, A., Hanis, J., Kurfirst, V., Eisenberger, M., Pesl, L., Sequential hybrid procedure for persistent atrial fibrillation. J Am Heart Assoc, 4(3), 2015, e001754.
242. 242 Neven, K., van Driel, V., van Wessel, H., et al. Safety and feasibility of closed chest epicardial catheter ablation using electroporation. [published correction appears in Circ Arrhythm Electrophysiol. 2014;7(6):1282] Circ Arrhythm Electrophysiol 7:5 (2014), 913–919.
243. 243 van Driel, V.J., Neven, K.G., van Wessel, H., et al. Pulmonary vein stenosis after catheter ablation: electroporation versus radiofrequency. Circ Arrhythm Electrophysiol 7:4 (2014), 734–738.
244. 244 DeSimone, C.V., Kapa, S., Asirvatham, S.J., Electroporation: past and future of catheter ablation. Circ Arrhythm Electrophysiol 7:4 (2014), 573–575.
245. 245 Sharma, A., Wong, D., Weidlich, G., et al. Noninvasive stereotactic radiosurgery (CyberHeart) for creation of ablation lesions in the atrium. Heart Rhythm 7:6 (2010), 802–810.
246. 246 Constantinescu, A., Lehmann, H.I., Packer, D.L., Bert, C., Durante, M., Graeff, C., Treatment planning studies in patient data with scanned carbon ion beams for catheter-free ablation of atrial fibrillation. J Cardiovasc Electrophysiol 27:3 (2016), 335–344.
247. 247 Bode, F., Blanck, O., Gebhard, M., et al. Pulmonary vein isolation by radiosurgery: implications for non-invasive treatment of atrial fibrillation. Europace 17:12 (2015), 1868–1874.
248. 248 Martinez, M.W., Kirsch, J., Williamson, E.E., et al. Utility of nongated multidetector computed tomography for detection of left atrial thrombus in patients undergoing catheter ablation of atrial fibrillation. JACC Cardiovasc Imaging 2:1 (2009), 69–76.
249. 249 Anter, E., Silverstein, J., Tschabrunn, C.M., et al. Comparison of intracardiac echocardiography and transesophageal echocardiography for imaging of the right and left atrial appendages. Heart Rhythm 11:11 (2014), 1890–1897.
250. 250 Hakalahti, A., Uusimaa, P., Ylitalo, K., Raatikainen, M.J., Catheter ablation of atrial fibrillation in patients with therapeutic oral anticoagulation treatment. Europace 13:5 (2011), 640–645.
251. 251 Kim, J.S., She, F., Jongnarangsin, K., et al. Dabigatran vs warfarin for radiofrequency catheter ablation of atrial fibrillation. Heart Rhythm 10:4 (2013), 483–489.
252. 252 Cappato, R., Marchlinski, F.E., Hohnloser, S.H., et al., VENTURE-AF Investigators. Uninterrupted rivaroxaban vs. uninterrupted vitamin K antagonists for catheter ablation in non-valvular atrial fibrillation. Eur Heart J 36:28 (2015), 1805–1811.
253. 253 Lakkireddy, D., Reddy, Y.M., Di Biase, L., et al. Feasibility and safety of dabigatran versus warfarin for periprocedural anticoagulation in patients undergoing radiofrequency ablation for atrial fibrillation: results from a multicenter prospective registry. J Am Coll Cardiol 59:13 (2012), 1168–1174.
254. 254 Valles, E., Fan, R., Roux, J.F., et al. Localization of Atrial Fibrillation Triggers in Patients Undergoing Pulmonary Vein Isolation. Importance of the Carina Region. J Am Coll Cardiol 52:17 (2008), 1413–1420.
255. 255 Deshmukh, A., Patel, N.J., Pant, S., et al. In-hospital complications associated with catheter ablation of atrial fibrillation in the United States between 2000 and 2010: analysis of 93 801 procedures. Circulation 128:19 (2013), 2104–2112.